Rheumatology Flashcards

1
Q

How will you monitor this person on a biologic DMARD?

A

My considerations for patients on bDMARDS are

  • infusion reactions
  • increased risk of infection
  • malignancy
  • can cause demyelination / autoimmune phenomena

To monitor:

  • will need to continue regular review of disease activity to monitor therapeutic effect
  • ensure vaccinations are UTD and avoid live vaccines
  • routine biochemical monitoring with FBE/UEC/LFT
  • keep UTD with malignancy screening and skin checks
  • if requiring a surgical procedure, will need to be withheld several weeks prior in conjunction with Rheum team
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How will you monitor this person on Methotrexate?

A

Concerns are myelosuppression, hepatotoxicity and lung toxicity

  • FBE / UEC / LFT every 3 months
  • monitor for symptoms of above (SOB / infections)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How will you monitor this person on Leflunomide?

A

Concerns are GI upset, hepatotoxicity, HTN, ILD
Monitoring same as methotrexate =
- FBE / UEC / LFT every 3 months
- monitor for symptoms of above (SOB / infections / HTN)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How will you monitor this person on Azathioprine?

A

Concerns are GI upset, myelosuppression, infection, skin cancers
- FBE, skin checks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How will you monitor this person on Hydroxychloroquine?

A

Opthal review for retinal toxicity at baseline and then 5 year mark

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How will you determine activity of SLE?

A

Clinically

  • fatigue
  • severity of current symptoms
  • development of symptoms suggesting new organ manifestation

Biochemically

  • low complement
  • elevated dsDNA
  • active urinary sediment
  • cytopaenias
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How will you manage this person previously on cyclophosphamide?

A

Concerns:
- Infertility -> counselling
- Bladder -> annual urinalysis + cytology indefinitely
Also causes increased risk of haem malignancies

Whilst on it -> high risk of infection / myelosuppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How will you assess the activity of their inflammatory arthritis?

A

Clinically

  • degree of morning stiffness / fatigue / change in functional capacity
  • number of tender and swollen joints
  • active synovitis
  • development of extra-articular manifestations

Biochemically

  • CRP / ESR
  • albumin / plts

Radiologically
- XR to look for disease progression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are main extra-articular manifestations of RA?

A
  • Eyes-> epislceritis/uveitis/keratitis
  • Sicca symptoms
  • ILD
  • Serositis
  • Haematological -> cytopaenias / splenomegaly
  • Cutaneous vasculitis + neuropathy
  • Nodules
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What would your approach to treating a flare of RA be?

A

In an acute flare:

  • if one / few joints involved -> could consider local steroid injection
  • if widespread -> initiating/increasing level of systemic steroid, to then wean when flare resolved
  • if recurrent flares, then background DMARD therapy needs to be escalated in conjunction with Rheum
  • > dose increase
  • > decrease interval of dosing
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is a myositis ab panel?

A
CK
U1RNP
SRP
Jo-1
MI-2
(can also do lupus / Sjogren's ab)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are poor prognostic factors in RA?

A
Clinical = 
- high number of joints affected
- extra-articular features 
- significant functional limitations
Biochemical = 
- seropositivity
- early erosions
- high inflam markers
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is difference between AL / AA amyloidosis?

A

AL -> refers to ‘primary’ amyloidosis.
A complication of plasma cell dyscrasia with deposition of light chain fragments in organs
AA -> ‘secondary’, complicates chronic inflammatory diseases. It is fragments of an acute phase reactant serum amyloid A protein that is deposited
Can also have organ-specific amyloid, or dialysis-related

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are manifestations to ask about in AL amyloidosis?

A
  • Mucocutaneous
  • Renal -> nephrotic syndrome
  • Neuro -> neuropathy
  • Cardiac infiltration
  • GIT -> haemorrhage / malabsorption
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the main manifestations of sarcoidosis to ask about?

A
  • Lung -> diffuse ILD, can have pulm HTN
  • Eyes -> uveitis / plaques
  • Cardiac
  • Neuro -> nerve palsies
  • Renal -> - Hypercalcaemia / hypercalciuria
  • Skin -> erythema nodosum, rash, plaques
  • Arthritis
  • Endocrine infiltration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are main manifestations of SSc?

A
  • skin (sclerosis / Raynaud’s, calcinosis, telangectasias)
  • sicca symptoms
  • renal crisis (triggered by pred use)
  • cardiac -> restrictive CM
  • GIT -> oesohageal dysmotility, constipation, GI bleeding
  • Lung -> ILD, pulm HTN
  • MSK -> arthralgias, myositis
  • Neuro -> neuropathy
17
Q

How to differentiate between diffuse and limited SSc?

A
  • Skin sclerosis does not extend beyond elbows in limited, not on trunk
  • anti-centromere ANA pattern in limited
18
Q

What are the features of MCTD?

A

Clinical

  • overlap of SLE, SSc and PM
  • swollen hands, arthritis
  • Raynaud’s
  • myositis
  • pulm HTN

Biochemical
- Anti-U1RNP

19
Q

How will you differentiate between RA and OA?

A

Pattern of stiffness -> morning / later
DIP involvement / Heberden’s nodes in OA
Type of swelling -> bony vs boggy
Ix -> XRs showing erosions/cysts; and elevated inflam markers in RA

20
Q

What are extra-articular manifestations of spondyloarthropathies?

A

Eyes - uveitis
Skin - psoriasis, dactylitis
Enthesitis
Bowel - IBD

21
Q

Gout Management Spiel

A

My approach to management will be

  • rapid identification and Rx of flares
  • Prevention of future attacks to avoid complications (e.g. renal, joint)

Prevention
- Lifestyle: addressing CVRFs, reducing triggers e.g. thiazides, substitute losartan, minimise ETOH and purine-rich foods

  • Pharm:
    -> utilising urate-lowering therapy with treat to target approach, with flare prophylaxis
    1st line = allopurinol, then can add probenacid
    2nd line = febuxostat (not in CVD)

I will ensure regular monitoring of uric acid levels and progress